Tempus: Diagnostics Substance, AI Flash [Seeking Alpha]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Seeking Alpha
TEM's recent large acquisition of Ambry Genetics signals a push for growth, but raises concerns about infrastructure readiness and increasing financial leverage. The company's FDA-approved AI algorithms offer incremental, not revolutionary, improvements, and analyst sentiment discounts near-term AI-driven revenue growth. With a lofty price-to-sales ratio and slow AI progress, TEM appears overvalued relative to peers; current fundamentals suggest caution and a 'wait-and-see' approach. BlackJack3D/E+ via Getty Images Back in March of this year, we talked at length about applications of AI to the drug discovery process in the context of Recursion Pharmaceuticals ( RXRX ). During that conversation, we mentioned another AI healthcare This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of GOOG either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not rec
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Lightning Round: Recursion Pharmaceuticals and NuScale Power [CNBC]CNBC
- Cramer's Lightning Round: Recursion Pharmaceuticals ‘has been horrendous' [CNBC]CNBC
- Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025GlobeNewswire
- Is Recursion Pharmaceuticals a Meme Stock? [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader? [Seeking Alpha]Seeking Alpha
RXRX
Earnings
- 11/5/25 - Beat
RXRX
Sec Filings
- 12/4/25 - Form 4
- 12/4/25 - Form 144
- 12/2/25 - Form 144
- RXRX's page on the SEC website